41 results
Page 2 of 3
424B5
kl9rkcn73806u
22 Jan 20
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
pk8p5lq1ch7da zyh
13 Jan 20
Results of Operations and Financial Condition
6:07am
8-K
EX-99.1
esxmpztf
17 Dec 19
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
8-K
xkrpgkqcfbt3i160xu
17 Dec 19
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
8-K
EX-99.1
ewmc 70k6nw
1 Nov 19
ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results
6:54am
8-K
jgcifx
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
8-K
EX-99.3
q6v smk2q1ew
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
8-K
EX-99.1
0rgl0
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
8-K/A
EX-99.1
65nw0g6bn
2 Aug 19
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
10:33am
8-K
EX-99.1
jbat3t7sknnp0h0x9ahz
2 Aug 19
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
6:38am
8-K
EX-99.1
id30u5wmle4edx0y
27 Jun 19
ImmunoGen Announces Completion of Operational Review
6:35am
8-K
EX-99.1
z0ox3ghyr
8 Feb 19
ImmunoGen Reports Recent Progress and 2018 Operating Results
6:37am
8-K
EX-99.1
509v 9facptw
27 Jul 18
ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results
6:35am
424B5
oyp31t rm62gnk9n
7 Jun 18
Prospectus supplement for primary offering
4:31pm
424B5
3iz3pwjj c4nt6la7y3
5 Jun 18
Prospectus supplement for primary offering
5:17pm
8-K
EX-99.1
77r j9360atxq
26 Apr 18
FORWARD I trial has completed full enrolloment; top-line results expected in the first half of 2019
12:00am